Fraunhofer ITEM: High-Performance-Center Translational Medical Engineering
Together with representatives from industry, government and academia, Dr. Gabriele Heinen-Kljajić, Minister for Science and Culture of Lower Saxony, and Prof. Reimund Neugebauer, President of the Fraunhofer-Gesellschaft inaugurated the High-Performance Center Translational Biomedical Engineering in Hannover on April 25.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170425006452/en/
Representatives from industry, government and academia have opened the High-Performance Center Translational Medical Engineering: (from left to right) Dr. Gabriele Heinen-Kljajić, Minister for Science and Culture of Lower Saxony, Prof. Theodor Doll, Head of the High-Performance Center, Prof. Norbert Krug, Director of Fraunhofer ITEM, Prof. Reimund Neugebauer, President of the Fraunhofer-Gesellschaft, Prof. Christopher Baum, President of the Hannover Medical School, and Prof. Thomas Lenarz, Professor and Chairman of the Department of Otorhinolaryngology of the Hannover Medical School (sitting at the front). (Photo: Business Wire)
The Center is aimed at bringing medical devices from the lab into phase I of clinical development. The focus is on active implants and technological solutions for inhaled drug delivery. The latter are systematically developed towards smart-drug/device combination products. The Center is funded by the Lower-Saxony government and the Fraunhofer-Gesellschaft. “Be it research on and development of implants, regenerative or personalized medicine – we want to contribute to overcoming the difficult step of transferring medical research results into clinical application, so that patients can benefit from novel products and methods. The new High-Performance Center Translational Biomedical Engineering provides a valuable link between research institutions and industry. It further strengthens the close network of research in the life sciences in Hannover,” said Heinen-Kljajić.
“In this Center, we will assist researchers, companies and entrepreneurs from the very phase of development. Dedicated manufacturing processes, for example, commonly represent substantial economic hurdles for small and medium-sized enterprises. Furthermore, medical devices equally have to go through quality assurance and risk assessment processes, before they can progress to clinical trials. We guide through the sophisticated processes of bringing devices from basic research to clinical application,” said Prof. Theodor Doll, head of the Center. Doll is holding a professorship instituted at the Hannover Medical School in collaboration with Fraunhofer ITEM. It directly connects the research done in the clusters of excellence REBIRTH and “Hearing4all” in Hannover and in the Lower-Saxony consortium “Biofabrication for NIFE” with the Fraunhofer ITEM translation expertise.
“Within a very short time, the High-Performance Centers of the Fraunhofer-Gesellschaft have proven to excellently support cooperation with universities and industry. The aim is to broadly promote research and education, training and continuing professional development, career opportunities for both young and senior scientists, and the transfer from lab to fab. The High-Performance Centers shall be established as infrastructure for this transfer,” explained Neugebauer. “The new Translational Biomedical Engineering Center provides optimal opportunities to step into a top position in innovative medical device development. Together with our partners, we can provide decisive impetus for future innovations to industry, SMEs and start-ups in the medical sector.”
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom